The recent reductions in the US Food and Drug Administration’s workforce are poised to have a substantial impact on drug and biologic ...

CEO Stephen Glover said, “ZyVersa is developing Cholesterol Efflux Mediator VAR 200 for treatment of chronic kidney diseases, initially ...

To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unmet need is ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

UK biotech Compass Pathways is planning ... its plans to develop the drug known as COMP360, which is a crystalline formulation of psilocybin in phase 2b clinical development in patients who ...

The U.S. Food and Drug Administration said on Thursday it plans to replace animal testing in the development of monoclonal ...

The FDA will begin replacing animal testing in the development of monoclonal antibody therapies and other drugs with ...

Scientists have helped identify a novel drug compound that selectively activates pain-altering receptors in the body, offering a potentially safer alternative to conventional pain medications.

The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...

Scientists have re-created a pain pathway in the brain by growing four key clusters of human nerve cells in a dish. This ...

Imcivree’s initial FDA approval in 2020 covered chronic weight management caused by three rare protein deficiencies that impair the MC4 receptor pathway. In 2022, the Rhythm drug expanded its ...